This evidence let us confirm SMARCB1 as a tumor suppressor in lung cancer and prompted us to investigate lung cancer progression and response to the EGFR-TKI-afatinib at in vivo (nu-/nu-) mice model. Here, SMARCB1 is linked to lung carcinoma.